Member Info for ak_gabba

ShuanP has IT-IS staff as 14 in his files.

Thats quite a jump!

hi Wilson63,

Thats essentially my query. I notice they have a product for this type of infection but i haven't heard anything further about the assay they referred to on the 24th Feb.

Seeing the articles about these infections along with mucormycosis coming from India reminded me they were working on something. I haven't been able to spot anything further so checking in to see if anyone else has any info in this area.

From the 24th Feb R&D update

https://www.lse.co.uk/rns/NCYT/research-and-development-update-7iu0u64rk16dtin.html

"Development of a new test panel to detect aspergillosis fungal infections

Aspergillosis is an infection caused by aspergillus fungus common in immune compromised patients4, and more recently has been associated with co-infection in patients with SARS-CoV-25 infections and COVID-19-associated pulmonary aspergillosis6. The infection is associated with long-term ventilation of patients. Outside of SARS-CoV-2 infections, aspergillosis also remains a potentially serious respiratory infection, affecting ~5 million patients worldwide"

I noticed https://www.genesig.com/products/9138-aspergillus however the handbook has a published date of 09/11/2018

I don't have any information on this panel being available however we are still in Q2 2021. Does anyone have any further update on this?

It looks like India is having problems with these infections along with mucormycosis (sometimes referred to as black fungus)

https://indianexpress.com/article/cities/mumbai/fungal-infections-mucormycosis-candidiasis-aspergillosis-common-among-covid-patients-7308667/

I see what you mean. Don't have an answer however they did use SNPsig which is registered to novacyt

Thanks to Larry on twitter finding this

https://twitter.com/Larry64450205/status/1391061137223979020

Works out to be just shy of £300,000 going by todays exchange rate.

mapper99,

they appear to be releasing a few months at the same time now. i think it could 2 or 3 months before the next ones are released however we don't have a current contract with DHSC and the framework has changed. i'm unsure if further sales into the NHS network will be covered through DHSC spending.

Unable to paste the details in here as the formatting goes all wrong. Twitter displays it better.

https://twitter.com/ak_gabba/status/1390387638960537604

TU update 9th Apr (yes that one)

"Novacyt delivered revenue for Q1 2021 of €83.0 million (£72.6 million). Approximately 50% of Q1 revenue was driven by sales to the DHSC, predominately PROmate™. The remaining c.50% of Q1 revenue was driven by continued growth of international sales and expansion of the Company's private sector testing operations."

The DHSC spend spreadsheets are showing testing kits of £47,922,948.00

Thats more than 50% of £72m

and yes no invoices registered for Dec 2020 or Jan 2021

according to the DHSC departmental spend over £25k

PRIMERDESIGN LTD have had

£191,388,863.23

B2HS2L,

It's just been updated. Dec 2020, Jan 2021 and Feb 2022

Hope this pastes well

2020

Row Labels Sum of Amount
PRIMERDESIGN LTD £143,462,233.63
Lab Facilities £9,349,915.68
Aug £6,535,267.20
Sep £1,237,740.00
Oct £1,576,908.48
Maintenance services & support £110,619.60
Nov £110,619.60
Test Kits £41,689,643.95
Jul £9,943,730.35
Oct £31,745,913.60
Testing Kits £92,263,555.20
Nov £92,263,555.20
Testing Kits £48,499.20
Sep £48,499.20
Grand Total £143,462,233.63

2021

Row Labels Sum of Amount
PRIMERDESIGN LTD £47,926,629.60
Maintenance Services and Support £3,681.60
Feb £3,681.60
Testing kits £47,922,948.00
Feb £47,922,948.00
Grand Total £47,926,629.60

neilrich3,

https://novacyt.com/executive-management/

We suspect Nick Plummer may well be busy dealing with the DHSC dispute

"Corporate/commercial solicitor with over 25 years’ experience in large law firms (Ashurst, Keystone Law) and running in-house legal functions (Ark Therapeutics Group PLC and Patheon/Thermo Fisher Scientific), specialising in healthcare.
Prior to Novacyt, Nick spent eight years working as EU Managing Counsel for Patheon (then Thermo Fisher), supporting the drug product development and manufacture business."

David Franks appointment is interesting when you look at the bullet points on the link

"25 years corporate and advisory experience across a range of cultures and operating contexts
Track record of transformation and change, with a focus on scaling for growth and building organisational capability"

Scaling for growth caught my interest.

I think that is old news

https://www.gov.uk/government/news/uk-company-delivers-over-40000-pcr-test-kits-to-egypt

butchers,

21 products :)

https://www.lab-innovations.com/?utm_source=media-partner&utm_campaign=The%20NEC%20website%20listing&utm_medium=none

https://www.lab-innovations.com/exhibitor/novacyt-group/

letdown, 18 months ago is Oct 2019. Your initial buy in price would be below 7p per share. Even if you only threw £1000 at it you'd have over 14,000 shares which would be worth more than £60,000

Ha! That made me chuckle

the recruitment drive appears to have slowed down in recent weeks. Perhaps they have already been filled. There were a number of job postings directly after the dispute was announced and of course there was a recent RNS indicating over 50 field specialists servicing the NHS.
Not all jobs get advertised on job boards. I'm unsure how much head hunting goes on in that field.

Thanks Wilson63 and Victory_Sci

"quickly becoming a market standard in the USA"

I like that quote!

Flushfrank,
Yes I quiried that earlier on. It mentions countries (plural).
It highlights acceptance of feedback and the willingness to respond. I'm hopeful it will lead to increased business international revenues.

"Due to an emerging need in some countries, the Company expects to launch a second CE-IVD PROmate™ COVID-19 test in May 2021 to identify both the SARS-CoV-2 ORF1ab gene and M gene"

This was encouraging from todays RNS. It suggests they are reacting to feedback from other countries (plural) and responding to it.

You can maybe add.
Yas, ya dancer!